By Lizzy Smith | Posted - Jan 29th, 2015

 

 

 

 

Early Myeloma Diagnosis And Proper Treatment Impacts Outcomes

For those diagnosed with multiple myeloma, selecting the proper treatment has a big impact on outcomes. But before proper treatment options can be identified, it is critical to know as much about the patient's specific disease first. Better testing is helping determine best options by the individual patient, as opposed to the once "one size fits all" approach. Over the past decade, proteasome inhibitors and other drugs have provided improved outcomes and survival in myeloma, though most patients relapse. With the use of modern diagnosis, however, myeloma specialists are increasingly becoming better able to treat those with refractory/relapse disease. Two new drugs are helping: Pomalyst and Kyprolis. According to a press release from Market Research Reports, Inc, precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of improved diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. The promising news is that there are emerging new treatments, which includes combination of small molecules and biologics, and novel approach of molecular analysis of multiple myeloma. The rivalry prevalent in the global oncology-diagnostic and therapeutic myeloma market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Read more: https://www.digitaljournal.com/pr/2448068#ixzz3QF10Ycoe

 
Lizzy Smith
About the Author

Lizzy Smith - Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS

Thanks to our Myeloma Crowd Community sponsors:

.